Jeito Capital’s Dr. Rafaèle Tordjman Appointed to Promote the French Biotech Ecosystem

  • The appointment of Dr. Tordjman was granted by French Ministers, Agnès Pannier-Runacher and Franck Riester

Paris, France, 28 July 2021 – Jeito Capital (“Jeito”), a rapidly emerging independent Private Equity firm dedicated to biotech and biopharma, today welcomes the appointment of Dr. Rafaèle Tordjman, Founder and CEO of Jeito, by Agnès Pannier-Runacher, Minister Delegate for Industry and Franck Riester, Minister Delegate for Foreign Trade and Economic Attractiveness to promote the French biotech ecosystem among leading international players.

With this appointment made today, Dr. Tordjman will promote globally the opportunities offered by the French biotech ecosystem to talented and experienced individuals, which are currently based abroad. With her expertise in the field of medical-pharmaceuticals and her deep knowledge and experience in financing startups, she will help advise the French Government in how to attract global talent and entrepreneurs to the French ecosystem.

Franck Riester, Minister Delegate for Foreign Trade and Economic Attractiveness, said: “We are fortunate to have one of the most dynamic tech ecosystems in the world in France, particularly in the medtech and biotech sectors, where our startups shine with their capacity for innovation. We have been able to meet the challenge of financing. To assert themselves in a globally competitive environment, our future champions only need one thing: to attract the best talent!”

Agnès Pannier-Runacher, Minister Delegate for Industry, added:The COVID-19 crisis has provided insight into the importance of innovative healthcare companies. Progress in biotechnology calls for action because tomorrow’s healthcare is being built today. France wants to facilitate all entrepreneurial initiatives that can contribute to this. Dr. Rafaèle Tordjman is leading a mission to attract the best talent, raise awareness of our ecosystem and identify the strengths that will make France more attractive to the biotechnology industry. This mission follows the decisions of the President of the Republic following the Strategic Council on Health Industries (CSIS), for which he announced a €7 billion plan. Our objective is simple: to make France a leading nation in healthcare innovation by 2030.”

Dr. Rafaèle Tordjman, Founder and CEO of Jeito Capital, commented:I am extremely honored to be entrusted to lead this mission and to promote raising awareness of the excellence of the French biotech ecosystem and healthcare innovation. Attracting talent across all sectors, from research to investment, is essential to promote entrepreneurship in the French healthcare sector, support and aid the development of our start-ups to become international leaders and further accelerate investment in this key sector.


About Jeito Capital

Jeito Capital is a global leading investment company with a patient benefit driven approach that finances and accelerates ground-breaking medical innovation. Jeito empowers and supports entrepreneurs through its expert, integrated, multi-talented team and through the investment of significant capital to ensure the growth of companies, building market leaders in their respective therapeutic areas with accelerated patients’ access in Europe & the United States. Jeito Capital is based in Paris with a presence in Europe and the United States. For more information, please follow @Jeito_life on Twitter or LinkedIn.